Freimut Schilling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Freimut Schilling has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Diezi
Pediatric Hematology and Oncology Unit, Department of Pediatrics, University Hospital Center Lausanne, Lausanne, Switzerland
5 shared publications - Pierluigi Brazzola
Institute of Pediatrics of Southern Switzerland, Cantonal Hospital Authority (EOC), Bellinzona, Switzerland, Bellinzona, Switzerland
5 shared publications - Katrin Scheinemann
Ostschweizer Kinderspital
4 shared publications - Anica Ilic
Faculty of Health Sciences and Medicine University of Lucerne Lucerne Switzerland
3 shared publications - Christina Schindera
University of Bern
3 shared publications - Claudia Elisabeth Kuehni
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Growth trajectories and risk of underweight and overweight in childhood cancer patients and survivors: a longitudinal multicentre cohort study protocol (Preprint)
BACKGROUND Underweight, overweight, and linear growth during and after cancer treatment can impact treatment efficacy and survival in childhood cancer patients, and long-term health in childhood cancer survivors (CCS). However, scientific evidence on the weight status and growth of CCS is limited. Previous studies have been small, focused on specific cancer types, or lacked objectively measured longitudinal data. The availability of standardized, semantically interoperable routine data from oncology clinics offers an unprecedented opportunity to investigate nutritional status across all childhood cancer types, treatment regimens, and critical time windows. OBJECTIVE We will investigate underweight, overweight, and growth trajectories from birth to adulthood in childhood cancer patients and survivors. We will identify predictors associated with distinct growth and weight trajectories and assess the consistency of findings across European countries. METHODS The Growth study will collect routinely recorded sociodemographic, clinical, and anthropometric data from paediatric and adolescent cancer patients (aged <20 years) from Switzerland, Portugal and Slovenia, We will include patients diagnosed between 2004-2026, by linking data from the Swiss Childhood Cancer Registry (ChCR), the Swiss Childhood Cancer Survivor Study (SCCSS), the Swiss Federal Statistical Office (FSO), and oncology clinics in Switzerland. Deterministic linkage of data sources (ChCR, SCCSS, oncology clinics, and FSO) will be performed using social security numbers. We will calculate age- and sex-specific z-scores for weight, height, and BMI based on country-specific and World Health Organization growth references. Latent trajectory modelling will be applied to identify distinct growth and weight trajectories and to detect subgroups at increased risk of growth impairment. We will use logistic regression models to identify predictors of impaired growth. RESULTS The project was funded in 2025; first study results are expected to be published by autumn 2027. We will obtain routinely collected data from approximately 12,250 childhood cancer patients and survivors - 7,800 from Switzerland, 3,350 from Portugal, and 1,100 from Slovenia. CONCLUSIONS The Growth study will provide insights into the nutritional status of childhood cancer patients and survivors and improve understanding of growth patterns in this population. Identifying high risk groups and tumour or treatment related factors will inform targeted surveillance strategies and early nutritional interventions. CLINICALTRIAL ClinicalTrials.gov NCT07750444
- 5 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessGrowth trajectories and risk of underweight and overweight in childhood cancer patients and survivors: a longitudinal multicentre cohort study protocol (Preprint)
BACKGROUND Underweight, overweight, and linear growth during and after cancer treatment can impact treatment efficacy and survival in childhood cancer patients, and long-term health in childhood cancer survivors (CCS). However, scientific evidence on the weight status and growth of CCS is limited. Previous studies have been small, focused on specific cancer types, or lacked objectively measured longitudinal data. The availability of standardized, semantically interoperable routine data from oncology clinics offers an unprecedented opportunity to investigate nutritional status across all childhood cancer types, treatment regimens, and critical time windows. OBJECTIVE We will investigate underweight, overweight, and growth trajectories from birth to adulthood in childhood cancer patients and survivors. We will identify predictors associated with distinct growth and weight trajectories and assess the consistency of findings across European countries. METHODS The Growth study will collect routinely recorded sociodemographic, clinical, and anthropometric data from paediatric and adolescent cancer patients (aged <20 years) from Switzerland, Portugal and Slovenia, We will include patients diagnosed between 2004-2026, by linking data from the Swiss Childhood Cancer Registry (ChCR), the Swiss Childhood Cancer Survivor Study (SCCSS), the Swiss Federal Statistical Office (FSO), and oncology clinics in Switzerland. Deterministic linkage of data sources (ChCR, SCCSS, oncology clinics, and FSO) will be performed using social security numbers. We will calculate age- and sex-specific z-scores for weight, height, and BMI based on country-specific and World Health Organization growth references. Latent trajectory modelling will be applied to identify distinct growth and weight trajectories and to detect subgroups at increased risk of growth impairment. We will use logistic regression models to identify predictors of impaired growth. RESULTS The project was funded in 2025; first study results are expected to be published by autumn 2027. We will obtain routinely collected data from approximately 12,250 childhood cancer patients and survivors - 7,800 from Switzerland, 3,350 from Portugal, and 1,100 from Slovenia. CONCLUSIONS The Growth study will provide insights into the nutritional status of childhood cancer patients and survivors and improve understanding of growth patterns in this population. Identifying high risk groups and tumour or treatment related factors will inform targeted surveillance strategies and early nutritional interventions. CLINICALTRIAL ClinicalTrials.gov NCT07750444
- Open Access
Growth trajectories and risk of underweight and overweight in childhood cancer patients and survivors: a longitudinal multicentre cohort study protocol
Background: Underweight, overweight, and linear growth during and after cancer treatment can impact treatment efficacy and survival in childhood cancer patients, and long-term health in childhood cancer survivors (CCS). However, scientific evidence on the weight status and growth of CCS is limited. Previous studies have been small, focused on specific cancer types, or lacked objectively measured longitudinal data. The availability of standardized, semantically interoperable routine data from oncology clinics offers an unprecedented opportunity to investigate nutritional status across all childhood cancer types, treatment regimens, and critical time windows. Objectives: We will investigate underweight, overweight, and growth trajectories from birth to adulthood in childhood cancer patients and survivors. We will identify predictors associated with distinct growth and weight trajectories and assess the consistency of findings across European countries. Methods: The Growth study will collect routinely recorded sociodemographic, clinical, and anthropometric data from paediatric and adolescent cancer patients (aged <20 years) from Switzerland, Portugal and Slovenia, We will include patients diagnosed between 2004-2026, by linking data from the Swiss Childhood Cancer Registry (ChCR), the Swiss Childhood Cancer Survivor Study (SCCSS), the Swiss Federal Statistical Office (FSO), and oncology clinics in Switzerland. Deterministic linkage of data sources (ChCR, SCCSS, oncology clinics, and FSO) will be performed using social security numbers. We will calculate age- and sex-specific z-scores for weight, height, and BMI based on country-specific and World Health Organization growth references. Latent trajectory modelling will be applied to identify distinct growth and weight trajectories and to detect subgroups at increased risk of growth impairment. We will use logistic regression models to identify predictors of impaired growth. Results: The project was funded in 2025; first study results are expected to be published by autumn 2027. We will obtain routinely collected data from approximately 12,250 childhood cancer patients and survivors - 7,800 from Switzerland, 3,350 from Portugal, and 1,100 from Slovenia. Conclusions: The Growth study will provide insights into the nutritional status of childhood cancer patients and survivors and improve understanding of growth patterns in this population. Identifying high-risk groups and tumour- or treatment-related factors will inform targeted surveillance strategies and early nutritional interventions.
Open AccessGrowth trajectories and risk of underweight and overweight in childhood cancer patients and survivors: a longitudinal multicentre cohort study protocol
Background: Underweight, overweight, and linear growth during and after cancer treatment can impact treatment efficacy and survival in childhood cancer patients, and long-term health in childhood cancer survivors (CCS). However, scientific evidence on the weight status and growth of CCS is limited. Previous studies have been small, focused on specific cancer types, or lacked objectively measured longitudinal data. The availability of standardized, semantically interoperable routine data from oncology clinics offers an unprecedented opportunity to investigate nutritional status across all childhood cancer types, treatment regimens, and critical time windows. Objectives: We will investigate underweight, overweight, and growth trajectories from birth to adulthood in childhood cancer patients and survivors. We will identify predictors associated with distinct growth and weight trajectories and assess the consistency of findings across European countries. Methods: The Growth study will collect routinely recorded sociodemographic, clinical, and anthropometric data from paediatric and adolescent cancer patients (aged <20 years) from Switzerland, Portugal and Slovenia, We will include patients diagnosed between 2004-2026, by linking data from the Swiss Childhood Cancer Registry (ChCR), the Swiss Childhood Cancer Survivor Study (SCCSS), the Swiss Federal Statistical Office (FSO), and oncology clinics in Switzerland. Deterministic linkage of data sources (ChCR, SCCSS, oncology clinics, and FSO) will be performed using social security numbers. We will calculate age- and sex-specific z-scores for weight, height, and BMI based on country-specific and World Health Organization growth references. Latent trajectory modelling will be applied to identify distinct growth and weight trajectories and to detect subgroups at increased risk of growth impairment. We will use logistic regression models to identify predictors of impaired growth. Results: The project was funded in 2025; first study results are expected to be published by autumn 2027. We will obtain routinely collected data from approximately 12,250 childhood cancer patients and survivors - 7,800 from Switzerland, 3,350 from Portugal, and 1,100 from Slovenia. Conclusions: The Growth study will provide insights into the nutritional status of childhood cancer patients and survivors and improve understanding of growth patterns in this population. Identifying high-risk groups and tumour- or treatment-related factors will inform targeted surveillance strategies and early nutritional interventions.
- Open Access
- 12 August 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 152, 109811
“It has never been exactly what I was looking for”: information needs of grandparents after a grandchild’s cancer diagnosis – results from a multicenter mixed-methods study (GROKids Project)
- 12 August 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 152, 109811
Open Access“It has never been exactly what I was looking for”: information needs of grandparents after a grandchild’s cancer diagnosis – results from a multicenter mixed-methods study (GROKids Project)
- Open Access
- 7 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71774
Longitudinal Analysis of Psychological Distress in Grandparents of Children With Cancer: Results From a Multicenter Cohort Study in Switzerland ( GROKids Project)
Objectives: This exploratory study assessed psychological distress of grandparents of children recently diagnosed with cancer within 2 years post‐diagnosis. We examined changes over time, identified associated factors, and compared distress levels with a comparison group (grandparents of survivors). Methods: Grandparents were recruited via parents of children recently diagnosed with cancer (within 3 months). Survivors (3–10 years post‐diagnosis) were asked to provide contact information of their grandparents (comparison group). Grandparents completed surveys at 3 (T1), 6 (T2), 12 (T3), and 24 months (T4) post‐diagnosis. The comparison group completed a questionnaire once. Psychological distress was assessed using the Brief Symptom Inventory‐18, with three subscales (depression, anxiety, somatization), and an overall score (Global Severity Index; GSI). Scores were T‐standardized. We used linear mixed models to compare distress across time points and linear regressions for between‐group differences (grandparents versus comparison group). Results: Forty‐one grandparents (mean age = 68 years, 59% female) of 20 patients participated. In the comparison group 133 grandparents (mean age = 72 years, 60% female) of 66 survivors (mean years post‐diagnosis = 6.7, SD = 2.3) participated. GSI scores were all below normative values. Increases in GSI were observed from T1 to T2 (24%) and T3 to T4 (26%). Greater distance from the child's hospital was associated with lower GSI ( β : −13.27, p = 0.033) and anxiety scores ( β : −5.50, p = 0.017). Grandfathers reported higher levels of somatization than grandmothers ( β : 4.00, p = 0.071). Older age was associated with lower anxiety ( β : −9.86, p = 0.042). Conclusion: Although most grandparents reported psychological distress within normative ranges, distress levels increased in some. Targeted interventions might help support grandparents of children with cancer.
- 7 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71774
Open AccessLongitudinal Analysis of Psychological Distress in Grandparents of Children With Cancer: Results From a Multicenter Cohort Study in Switzerland ( GROKids Project)
Objectives: This exploratory study assessed psychological distress of grandparents of children recently diagnosed with cancer within 2 years post‐diagnosis. We examined changes over time, identified associated factors, and compared distress levels with a comparison group (grandparents of survivors). Methods: Grandparents were recruited via parents of children recently diagnosed with cancer (within 3 months). Survivors (3–10 years post‐diagnosis) were asked to provide contact information of their grandparents (comparison group). Grandparents completed surveys at 3 (T1), 6 (T2), 12 (T3), and 24 months (T4) post‐diagnosis. The comparison group completed a questionnaire once. Psychological distress was assessed using the Brief Symptom Inventory‐18, with three subscales (depression, anxiety, somatization), and an overall score (Global Severity Index; GSI). Scores were T‐standardized. We used linear mixed models to compare distress across time points and linear regressions for between‐group differences (grandparents versus comparison group). Results: Forty‐one grandparents (mean age = 68 years, 59% female) of 20 patients participated. In the comparison group 133 grandparents (mean age = 72 years, 60% female) of 66 survivors (mean years post‐diagnosis = 6.7, SD = 2.3) participated. GSI scores were all below normative values. Increases in GSI were observed from T1 to T2 (24%) and T3 to T4 (26%). Greater distance from the child's hospital was associated with lower GSI ( β : −13.27, p = 0.033) and anxiety scores ( β : −5.50, p = 0.017). Grandfathers reported higher levels of somatization than grandmothers ( β : 4.00, p = 0.071). Older age was associated with lower anxiety ( β : −9.86, p = 0.042). Conclusion: Although most grandparents reported psychological distress within normative ranges, distress levels increased in some. Targeted interventions might help support grandparents of children with cancer.
- Open Access
- 10 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e87007
Improving Registration and Dataflows Between Pediatric Oncology Clinics and the Childhood Cancer Registry of Switzerland: Protocol for SwissPedCancer Quality Assurance Study
Background: Cancer registries are essential to monitor cancer incidence and survival to provide better quality cancer data for research. In Switzerland, the pediatric oncology units within pediatric hospitals actively report cancer cases, and the coding and registration team of the Childhood Cancer Registry (ChCR) enters data manually from medical files into the registry database. There are no automated data transfers or feedback loops between the pediatric oncology clinics and the ChCR. This ongoing process is time-consuming, inefficient, and a source of potential errors. Objective: SwissPedCancer aims to explore the options for automated data transfers from clinical data warehouses and feedback loops to make cancer registry processes more efficient. Methods: SwissPedCancer is a nested project within the national data stream initiative, the Swiss Pediatric Personalized Research Network (SwissPedHealth). Since September 2022, SwissPedHealth has developed and piloted structures to make routine clinical data from pediatric oncology clinics available for monitoring, benchmarking, and research in an interoperable, standardized, and quality-controlled way. SwissPedCancer expects to include approximately 2800 patients diagnosed with cancer before the age of 20 years between 2017 and 2023. The pediatric oncology clinics’ data and the manually validated ChCR data will be delivered separately to a secure national computing network for health-related data (Biomedical Information Technology). We will compare these two data sources to assess completeness (case ascertainment), accuracy (validity), and timeliness of cancer registration in the ChCR. We will evaluate data on diagnosis, treatments, underlying genetic disease, remission, relapse, and late effects. SwissPedCancer will provide a framework for optimizing standardized and uniform data transfers between pediatric oncology clinics and the ChCR and for other registries within Switzerland. Results: The project was funded in September 2022 and received ethics exemption in October 2023. Data extraction from participating hospitals and the ChCR is expected to commence in January 2026. Study results are anticipated to be available in summer 2026. Conclusions: SwissPedCancer aims to reduce manual workload while improving the completeness, accuracy, timeliness, and comparability of childhood cancer data in Switzerland. The project will contribute to a robust, interoperable, and sustainable national infrastructure supporting high-quality cancer registration, timely analyses, and evidence-based decision-making.
- 10 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e87007
Open AccessImproving Registration and Dataflows Between Pediatric Oncology Clinics and the Childhood Cancer Registry of Switzerland: Protocol for SwissPedCancer Quality Assurance Study
Background: Cancer registries are essential to monitor cancer incidence and survival to provide better quality cancer data for research. In Switzerland, the pediatric oncology units within pediatric hospitals actively report cancer cases, and the coding and registration team of the Childhood Cancer Registry (ChCR) enters data manually from medical files into the registry database. There are no automated data transfers or feedback loops between the pediatric oncology clinics and the ChCR. This ongoing process is time-consuming, inefficient, and a source of potential errors. Objective: SwissPedCancer aims to explore the options for automated data transfers from clinical data warehouses and feedback loops to make cancer registry processes more efficient. Methods: SwissPedCancer is a nested project within the national data stream initiative, the Swiss Pediatric Personalized Research Network (SwissPedHealth). Since September 2022, SwissPedHealth has developed and piloted structures to make routine clinical data from pediatric oncology clinics available for monitoring, benchmarking, and research in an interoperable, standardized, and quality-controlled way. SwissPedCancer expects to include approximately 2800 patients diagnosed with cancer before the age of 20 years between 2017 and 2023. The pediatric oncology clinics’ data and the manually validated ChCR data will be delivered separately to a secure national computing network for health-related data (Biomedical Information Technology). We will compare these two data sources to assess completeness (case ascertainment), accuracy (validity), and timeliness of cancer registration in the ChCR. We will evaluate data on diagnosis, treatments, underlying genetic disease, remission, relapse, and late effects. SwissPedCancer will provide a framework for optimizing standardized and uniform data transfers between pediatric oncology clinics and the ChCR and for other registries within Switzerland. Results: The project was funded in September 2022 and received ethics exemption in October 2023. Data extraction from participating hospitals and the ChCR is expected to commence in January 2026. Study results are anticipated to be available in summer 2026. Conclusions: SwissPedCancer aims to reduce manual workload while improving the completeness, accuracy, timeliness, and comparability of childhood cancer data in Switzerland. The project will contribute to a robust, interoperable, and sustainable national infrastructure supporting high-quality cancer registration, timely analyses, and evidence-based decision-making.
- Open Access
- 1 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Resilience and post-traumatic stress symptoms in grandparents following their grandchild’s cancer diagnosis from a multicenter cohort study in Switzerland (The GROKids project)
Background: Resilience is the dynamic ability to adapt to adversity using personal and social resources. Childhood cancer represents a major family stressor, and grandparents often provide emotional, practical, and financial support. Yet, their psychosocial outcomes and resilience remain poorly understood. We aimed to: (1) identify resilience trajectories (2), examine their association with post-traumatic stress symptoms, and (3) determine factors influencing resilience. Methods: This multicenter cohort study included grandparents of children recently diagnosed with cancer and treated at one of eight participating pediatric oncology centers in Switzerland. Eligible grandparents were recruited and completed questionnaires at 3-, 6-, 12-, and 24- months post-diagnosis. Resilience (CD-RISC 10), post-traumatic stress symptoms (IES-R), information needs, health literacy (HLS-EU-Q12), partnership quality, and social support (MSPSS) were measured. We used group-based trajectory modeling to identify resilience trajectories (Aim 1), linear mixed models to examine associations of resilience trajectories with post-traumatic stress symptoms (Aim 2), and linear mixed-effects models to identify the internal and external resources for resilience (Aim 3). Results: We included data of 41 grandparents of 20 children with cancer. Mean age was 67.6 years; most were grandmothers ( n = 25, 61%), unemployed or retired ( n = 23, 59%), and partnered ( n = 35, 90%). Two resilience trajectories emerged within two years after diagnosis: low-stable ( n = 17, 43%) and high-declining ( n = 23, 57%). Grandparents in the low-stable group reported significantly higher post-traumatic stress symptoms (β: -19.8, 90% CI -29.2, -10.4, p < 0.001). The following internal resources were positively associated with resilience: higher health literacy (β: 0.31, 90% CI 0.20, 0.42, p < 0.001), more information received (β: 1.53, 90% CI 1.27, 1.79, p < 0.001), and having income that meets needs (β: 7.56, 90% CI 1.86, 13.26, p = 0.029). No external resources showed significant associations. Conclusion: Timely, clear, and tailored information may help strengthen grandparents’ resilience and reduce stress.
- 1 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessResilience and post-traumatic stress symptoms in grandparents following their grandchild’s cancer diagnosis from a multicenter cohort study in Switzerland (The GROKids project)
Background: Resilience is the dynamic ability to adapt to adversity using personal and social resources. Childhood cancer represents a major family stressor, and grandparents often provide emotional, practical, and financial support. Yet, their psychosocial outcomes and resilience remain poorly understood. We aimed to: (1) identify resilience trajectories (2), examine their association with post-traumatic stress symptoms, and (3) determine factors influencing resilience. Methods: This multicenter cohort study included grandparents of children recently diagnosed with cancer and treated at one of eight participating pediatric oncology centers in Switzerland. Eligible grandparents were recruited and completed questionnaires at 3-, 6-, 12-, and 24- months post-diagnosis. Resilience (CD-RISC 10), post-traumatic stress symptoms (IES-R), information needs, health literacy (HLS-EU-Q12), partnership quality, and social support (MSPSS) were measured. We used group-based trajectory modeling to identify resilience trajectories (Aim 1), linear mixed models to examine associations of resilience trajectories with post-traumatic stress symptoms (Aim 2), and linear mixed-effects models to identify the internal and external resources for resilience (Aim 3). Results: We included data of 41 grandparents of 20 children with cancer. Mean age was 67.6 years; most were grandmothers ( n = 25, 61%), unemployed or retired ( n = 23, 59%), and partnered ( n = 35, 90%). Two resilience trajectories emerged within two years after diagnosis: low-stable ( n = 17, 43%) and high-declining ( n = 23, 57%). Grandparents in the low-stable group reported significantly higher post-traumatic stress symptoms (β: -19.8, 90% CI -29.2, -10.4, p < 0.001). The following internal resources were positively associated with resilience: higher health literacy (β: 0.31, 90% CI 0.20, 0.42, p < 0.001), more information received (β: 1.53, 90% CI 1.27, 1.79, p < 0.001), and having income that meets needs (β: 7.56, 90% CI 1.86, 13.26, p = 0.029). No external resources showed significant associations. Conclusion: Timely, clear, and tailored information may help strengthen grandparents’ resilience and reduce stress.
- Open Access
- 28 November 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 143-154
Health‐Related Quality of Life in Adult Patients With von Willebrand Disease From Germany: Results of the WIL‐QoL Study
Introduction: Assessment of health‐related quality of life (HRQoL) is relatively new in von Willebrand disease (VWD). So far, generic questionnaires have mainly been used for HRQoL assessment in VWD. Aims: To assess generic and disease‐specific HRQoL in adult VWD patients and compare HRQoL with the general German population. Methods: Patients presenting with a personal or family history of bleeding and von Willebrand factor (VWF)‐specific laboratory parameters were enrolled in the WIL‐QoL study. HRQoL was assessed with generic (SF‐36) and disease‐specific (VWD‐QoL) questionnaires. Descriptive and inferential statistical procedures were applied based on a significance level at α ≤ 5%. Results: In the retrospective, multicentre WIL‐QoL study, HRQoL and clinical data in 120 adults with VWD (one adolescent completed the adult questionnaire) from 10 centres in Germany were collected. Compared to the corresponding age group in the general German population, female VWD patients had significantly worse HRQoL in all SF‐36 domains and male patients only in the ‘physical functioning’ domain. In the VWD‐QoL, highest impairments were seen in all VWD patients in the domains ‘other physicians’, ‘treatment’ and ‘sport & leisure’. VWD patients with a more significant disease burden, such as a bleeding score ≥ 9 ( p < 0.0001), long‐term prophylaxis ( p = 0.003), and VWD‐type 3 ( p = 0.022), reported significantly worse HRQoL. No HRQoL differences were seen between male and female VWD patients. Conclusion: Female VWD patients showed significant impairments in their HRQoL compared to the age group‐related general population. Compared to SF‐36, the VWD‐QoL identified stronger significant HRQoL differences in most VWD subgroups, confirming the impact of bleeds.
- 28 November 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 143-154
Open AccessHealth‐Related Quality of Life in Adult Patients With von Willebrand Disease From Germany: Results of the WIL‐QoL Study
Introduction: Assessment of health‐related quality of life (HRQoL) is relatively new in von Willebrand disease (VWD). So far, generic questionnaires have mainly been used for HRQoL assessment in VWD. Aims: To assess generic and disease‐specific HRQoL in adult VWD patients and compare HRQoL with the general German population. Methods: Patients presenting with a personal or family history of bleeding and von Willebrand factor (VWF)‐specific laboratory parameters were enrolled in the WIL‐QoL study. HRQoL was assessed with generic (SF‐36) and disease‐specific (VWD‐QoL) questionnaires. Descriptive and inferential statistical procedures were applied based on a significance level at α ≤ 5%. Results: In the retrospective, multicentre WIL‐QoL study, HRQoL and clinical data in 120 adults with VWD (one adolescent completed the adult questionnaire) from 10 centres in Germany were collected. Compared to the corresponding age group in the general German population, female VWD patients had significantly worse HRQoL in all SF‐36 domains and male patients only in the ‘physical functioning’ domain. In the VWD‐QoL, highest impairments were seen in all VWD patients in the domains ‘other physicians’, ‘treatment’ and ‘sport & leisure’. VWD patients with a more significant disease burden, such as a bleeding score ≥ 9 ( p < 0.0001), long‐term prophylaxis ( p = 0.003), and VWD‐type 3 ( p = 0.022), reported significantly worse HRQoL. No HRQoL differences were seen between male and female VWD patients. Conclusion: Female VWD patients showed significant impairments in their HRQoL compared to the age group‐related general population. Compared to SF‐36, the VWD‐QoL identified stronger significant HRQoL differences in most VWD subgroups, confirming the impact of bleeds.
- 19 November 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 174-184
Clinical, Obstetric‐Gynaecological and HRQoL Data of Female VWD Patients in the WIL‐QoL Study
Introduction: Von Willebrand disease (VWD) is one of the most common hereditary disorders of primary haemostasis. Females with VWD often report heavy menstrual bleeding (HMB) that can significantly impact health‐related quality of life (HRQoL). Aim: To analyse clinical and HRQoL data of females with VWD from the WIL‐QoL study. Methods: Clinical and obstetric‐gynaecological data were collected by a physician‐led clinical questionnaire and HRQoL data via a patient‐reported VWD‐specific questionnaire (VWD‐QoL). Results: Data on menstruation were available from 113 females with VWD (15 post‐menarche girls [mean age 14.8 ± 1.7 years] and 98 women [mean age 37.8 ± 12.6 years]). HMB (defined as increased [simultaneous use/replacement of sanitary pads/tampons every 1–2 h] and/or prolonged [>7 days] menstrual bleeding) was reported in 85% and 77% of girls and women, respectively. Of 72 women who became pregnant, 31 experienced bleeding during pregnancy (3 women had missing data) and 32 women reported at least one miscarriage (44%). Overall, 12/96 women (13%) underwent hysterectomy due to bleeding; these women had more moderate‐to‐severe VWD ( p < .006) and a higher bleeding score ( p < .013) than women who did not undergo hysterectomy. Women still experiencing menstruation ( n = 71) who ‘often/all the time’ self‐reported HMB (HMB‐PRO), pain during menstruation and impairments in everyday‐life activities due to menstruation had significantly worse HRQoL compared with those who ‘never/rarely’ reported these impacts ( p = .004, p < .001 and p < .001, respectively). Women who underwent hysterectomy reported significantly worse HRQoL than those who did not ( p < .007). Conclusion: Female VWD patients experienced substantial disease and HRQoL burden that is further exacerbated by HMB.
- 19 November 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 174-184
Clinical, Obstetric‐Gynaecological and HRQoL Data of Female VWD Patients in the WIL‐QoL Study
Introduction: Von Willebrand disease (VWD) is one of the most common hereditary disorders of primary haemostasis. Females with VWD often report heavy menstrual bleeding (HMB) that can significantly impact health‐related quality of life (HRQoL). Aim: To analyse clinical and HRQoL data of females with VWD from the WIL‐QoL study. Methods: Clinical and obstetric‐gynaecological data were collected by a physician‐led clinical questionnaire and HRQoL data via a patient‐reported VWD‐specific questionnaire (VWD‐QoL). Results: Data on menstruation were available from 113 females with VWD (15 post‐menarche girls [mean age 14.8 ± 1.7 years] and 98 women [mean age 37.8 ± 12.6 years]). HMB (defined as increased [simultaneous use/replacement of sanitary pads/tampons every 1–2 h] and/or prolonged [>7 days] menstrual bleeding) was reported in 85% and 77% of girls and women, respectively. Of 72 women who became pregnant, 31 experienced bleeding during pregnancy (3 women had missing data) and 32 women reported at least one miscarriage (44%). Overall, 12/96 women (13%) underwent hysterectomy due to bleeding; these women had more moderate‐to‐severe VWD ( p < .006) and a higher bleeding score ( p < .013) than women who did not undergo hysterectomy. Women still experiencing menstruation ( n = 71) who ‘often/all the time’ self‐reported HMB (HMB‐PRO), pain during menstruation and impairments in everyday‐life activities due to menstruation had significantly worse HRQoL compared with those who ‘never/rarely’ reported these impacts ( p = .004, p < .001 and p < .001, respectively). Women who underwent hysterectomy reported significantly worse HRQoL than those who did not ( p < .007). Conclusion: Female VWD patients experienced substantial disease and HRQoL burden that is further exacerbated by HMB.